PERSONAL DE APOYO
MACHADO MOUTINHO Lirane
congresos y reuniones científicas
Título:
ROLE OF THE GABAB RECEPTORS IN THE EFFECTS INDUCED BY NICOTINE ON ANXIETY-LIKE BEHAVIOUR IN MICE
Autor/es:
VARANI A; CALVO M; MOUTINHO L; INDUNI A; BALERIO G
Lugar:
Rosario- Argentina
Reunión:
Congreso; XLI Reunión Anual de la Sociedad Argentina de Farmacología Experimental; 2009
Institución organizadora:
SAFE
Resumen:
ROLE OF THE GABAB
RECEPTORS IN THE EFFECTS INDUCED BY NICOTINE ON ANXIETY-LIKE BEHAVIOUR IN MICE
Varani A 1, Calvo M 1, Moutinho L1,
Induni A1,2 and Balerio G1,2
1ININFA
(CONICET) y 2Cát. de Farmacología (FFYB, UBA) Junín 956,
5°Piso. Buenos Aires. E-mail: gbalerio@ffyb.uba.ar
The aim of the
present study was to evaluate the possible involvement of the GABAergic system
in the anxiolytic- and anxiogenic-like responses induced by nicotine (NIC) in
mice, using both pharmacological and genetic approaches. Animals were only
exposed once to NIC. The acute administration of low (0.05 mg/kg, sc) or high (0.8
mg/kg, sc) doses of NIC produced opposite effects in the elevated plus maze,
anxiolytic- anxiogenic-like responses, respectively. The effects of the
pretreatment with the GABAB receptor antagonist, 2-OH Saclofen (SAC)
(0.25, 0.5 and 1 mg/kg; ip) and the GABAB receptor agonist, baclofen
(BAC) (0.5, 1 and 2 mg/kg; ip), were evaluated on the anxiolytic- and
anxiogenic-like responses induced by NIC. SAC completely abolished these NIC-induced
effects (p<0.001; p<0.01, respectively) at the higher dose, suggesting an
involvement of GABAB receptor in these behavioural responses. On the
other hand, BAC failed to modify the effects induced by NIC on anxiety-like
behavior. In addition, in GABAB(1) knockout mice the anxiolytic-like
responses of NIC were blocked (p<0.001), suggesting a role of GABAB(1)
receptor in these behavioural responses, but not in the anxiogenic-like effects
of NIC. These results demonstrate that the endogenous GABAergic system is
involved in the regulation of NIC anxiety-like behaviour in mice and provide
new findings to support a potential pharmaco therapeutic use of GABAergic drugs
in the treatment of tobacco addiction. Supported
by UBACYT B016